NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Monday that its Fiscal Year 2013 first-quarter revenues increased 21 percent year over year.

The firm also upped its revenue and profit guidance for the year.

The Salt Lake City-based molecular diagnostics firm reported total revenues of $133.4 million for the three months ended Sept. 30, compared to $110.5 million for the first quarter of FY 2012. It beat analysts' consensus estimate of $129.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.